Noevir Holdings announces leadership restructure, new vice president

Noevir Holdings Co., Ltd. announced a series of leadership changes, effective December 9, 2025, aimed at strengthening its management structure. Ikkou Yoshida, currently a managing director, will assume the role of vice president and representative director. His career with Noevir began in January 1982, and he has held various key positions, including director and senior executive officer of management strategy. He holds 3,847 shares in the company.

The company also detailed changes across its board of directors, audit & supervisory board members, and executive officers. Takashi Okura remains as president and chief executive, while Hiroshi Okura continues as chairman and representative director. Kouzou Matsushita and Akihiro Keyari will continue as directors, also holding president and chief executive roles at Tokiwa Pharmaceutical Co., Ltd. and Noevir Co., Ltd., respectively.

Furthermore, Noevir Holdings provided an update on its controlling shareholder, Takashi Okura. As of September 30, 2025, Takashi Okura holds a total voting rights ratio of 50.14%, comprising 10.85% directly held and 39.29% subject to aggregation. The company emphasized its commitment to protecting minority shareholders by ensuring all transactions with controlling shareholders are conducted under appropriate terms and conditions, reviewed by the board of directors.